Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 12/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28014847 | 0.78 | ADORA1 (0.48) | ADORA1KDM4EALDH1A1MAPTMPI | |
| SCHEMBL2762751 | 0.74 | KDM4E (0.67) | ADORA1KDM4EALDH1A1MAPTMPI | |
| SCHEMBL14172770 | 0.73 | ALDH1A1 (0.48) | ADORA1KDM4EALDH1A1MAPTCYP3A4 | |
| SCHEMBL4490633 | 0.72 | ADORA1 (0.42) | ADORA1KDM4EALDH1A1MAPTMPI | |
| SCHEMBL1745165 | 0.71 | ADORA1 (0.97) | ADORA1KDM4EALDH1A1MAPTMPI | |
| SCHEMBL30953833 | 0.71 | ADORA1 (0.97) | ADORA1KDM4EALDH1A1MAPTMPI | |
| SCHEMBL8022641 | 0.70 | ACHE (0.81) | KDM4EALDH1A1NPC1RAB9AACHE | |
| Iodide SCHEMBL4957487 | 0.70 | ADORA1 (1.00) | ADORA1KDM4EALDH1A1MAPTMPI | |
| Iodide SCHEMBL3994859 | 0.70 | ADORA1 (0.59) | ADORA1KDM4EALDH1A1CHEK1DAPK3 | |
| SCHEMBL6885965 | 0.69 | MAPT (1.00) | ADORA1KDM4EALDH1A1MAPTMPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-16 | — | — | US | disclosed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2015164816-A2 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+-ACTIVATED K+ CHANNEL KCA3.1 AND THEIR METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | PHARMACIA ITALIA S.P.A. (IT) | 2004-10-14 | — | — | US | disclosed |
| EP-1406889-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | Pharmacia Italia S.p.A. (IT) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003006447-A2 | INTERACTION INHIBITORS OF TCF-4 WITH BETA-CATENIN | PHARMACIA ITALIA SPA (IT) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | KCNN3, KCNN1, KCNN2 | ADORA1 472/4885KDM4E 1597/4885ALDH1A1 3038/4885 |
| US-20040204477-A1 | Interaction inhibitors of tcf-4 with beta-catenin | TCF4, TCF7, TCF7L2 | ADORA1 4204/4885KDM4E 1700/4885ALDH1A1 1043/4885 |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | KCNN3, KCNN1, KCNN2 | ADORA1 472/4885KDM4E 1597/4885ALDH1A1 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.